Clinical Trials Browser

Interventional × Neoplasms × rovalpituzumab tesirine × Clear all

NCT03000257 2022-04-14

A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors

Phase 1 Completed

BreastDermatologicGastrointestinalGynecologicHead & NeckOther solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Mesothelioma, Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Carcinoma, Merkel Cell, Cholangiocarcinoma, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT03086239 2021-08-03

A Study on the Safety and Tolerability of Rovalpituzumab Tesirine in Japanese Patients With Advanced, Recurrent Small Cell Lung Cancer

Phase 1 Completed

Neoplasms, Small Cell Lung Carcinoma

NCT03033511 2021-07-29

MERU

Phase 3 Terminated

748 enrolled 13 charts

Neoplasms, Small Cell Lung Carcinoma

NCT03543358 2021-01-05

A Long-Term Study of Rovalpituzumab Tesirine

Phase 2 Completed

3 enrolled 6 charts

Neoplasms

NCT03026166 2020-07-17

A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer

Phase 1/2 Terminated

42 enrolled 15 charts

Neoplasms, Small Cell Lung Carcinoma

NCT03334487 2018-12-26

Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer

Phase 3 Withdrawn

Neoplasms, Small Cell Lung Carcinoma